RYTM (Rhythm Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

RYTM (Rhythm Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

Mkt Cap$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$190M

Net Income (TTM)-$197M

EPS (TTM)-$3.11

Free Cash Flow (TTM)-$117M

Gross Margin89.7%

Op. Margin-101.2%

Net Margin-103.6%

FCF Margin-61.5%

P/S Ratio (TTM)33.6x

P/E Ratio (TTM)—

YoY Rev Growth+45.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$11M	$10M	-$53M
Q2 23	$19M	$17M	-$47M
Q3 23	$23M	$20M	-$44M
Q4 23	$24M	$21M	-$41M
Q1 24	$26M	$23M	-$140M
Q2 24	$29M	$26M	-$40M
Q3 24	$33M	$29M	-$44M
Q4 24	$42M	$38M	-$41M
Q1 25	$33M	$29M	-$47M
Q2 25	$49M	$43M	-$45M
Q3 25	$51M	$46M	-$53M
Q4 25	$57M	$52M	-$47M

Valuation

Quarter	P/S	P/E
Q1 23	189.7x	—
Q2 23	145.7x	—
Q3 23	102.9x	—
Q4 23	82.4x	—
Q1 24	69.4x	—
Q2 24	62.6x	—
Q3 24	56.7x	—
Q4 24	49.0x	—
Q1 25	46.6x	—
Q2 25	40.8x	—
Q3 25	36.6x	—
Q4 25	33.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$36M	-$36M
Q2 23	-$41M	-$42M
Q3 23	-$29M	-$29M
Q4 23	-$29M	-$29M
Q1 24	-$41M	-$81M
Q2 24	-$29M	-$29M
Q3 24	-$25M	-$25M
Q4 24	-$19M	-$19M
Q1 25	-$40M	-$40M
Q2 25	-$23M	-$23M
Q3 25	-$27M	-$27M
Q4 25	-$25M	-$26M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$47K
Q2 23	$875K
Q3 23	$1K
Q4 23	$1K
Q1 24	$40M
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$953K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+665.6%	+18.1%
Q2 23	+112.0%	+21.5%
Q3 23	+425.3%	+52.6%
Q4 23	+175.7%	+28.7%
Q1 24	+126.4%	+159.1%
Q2 24	+51.3%	+5.7%
Q3 24	+47.8%	+16.1%
Q4 24	+72.6%	+26.8%
Q1 25	+25.9%	-51.9%
Q2 25	+66.8%	+34.9%
Q3 25	+54.3%	+34.8%
Q4 25	+36.9%	+25.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$6M	55.6%
Q2 23	$9M	46.3%
Q3 23	$9M	38.3%
Q4 23	$9M	35.8%
Q1 24	$8M	29.9%
Q2 24	$10M	35.6%
Q3 24	$11M	33.1%
Q4 24	$11M	25.2%
Q1 25	$13M	39.3%
Q2 25	$16M	32.7%
Q3 25	$19M	36.7%
Q4 25	$19M	33.7%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$38M	$25M
Q2 23	$34M	$30M
Q3 23	$34M	$30M
Q4 23	$30M	$32M
Q1 24	$128M	$34M
Q2 24	$30M	$36M
Q3 24	$38M	$35M
Q4 24	$41M	$38M
Q1 25	$37M	$39M
Q2 25	$42M	$46M
Q3 25	$46M	$52M
Q4 25	$42M	$57M

Revenue Segments

Quarter	Product revenue	Product
Q2 23	$19M	—
Q3 23	$23M	—
Q1 24	—	$26M
Q2 24	—	$29M
Q2 25	—	$49M
Q3 25	—	$51M

Revenue by Geography

Quarter	Germany	Other Countries	United States
Q3 24	$4M	$6M	$23M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$110M	$185M	$295M
Q2 23	$116M	$138M	$254M
Q3 23	$65M	$235M	$299M
Q4 23	$60M	$216M	$276M
Q1 24	$53M	$148M	$201M
Q2 24	$162M	$157M	$319M
Q3 24	$48M	$251M	$298M
Q4 24	$89M	$231M	$321M
Q1 25	$106M	$208M	$314M
Q2 25	$136M	$155M	$291M
Q3 25	$52M	$364M	$416M
Q4 25	$54M	$335M	$389M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	57M	+0.7%
Q2 23	57M	+0.3%
Q3 23	58M	+1.8%
Q4 23	59M	+2.3%
Q1 24	60M	+1.6%
Q2 24	61M	+1.4%
Q3 24	61M	+0.3%
Q4 24	62M	+0.6%
Q1 25	63M	+2.4%
Q2 25	64M	+1.0%
Q3 25	64M	+1.0%
Q4 25	67M	+3.9%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	$0	26
FY 18	$0	54
FY 19	$0	70
FY 20	$0	90
FY 21	$23K	140
FY 22	$134K	177
FY 23	$343K	226
FY 24	$460K	283
FY 25	$474	400K